<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.2 20190208//EN" "JATS-archivearticle1-mathml3.dtd"> 
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="review-article"><?DTDIdentifier.IdentifierValue http://null/schema/dtds/document/fulltext/xcr/xocs-article.xsd?><?DTDIdentifier.IdentifierType schema?><?SourceDTD.DTDName xocs-article.xsd?><?SourceDTD.Version 1.0?><?ConverterInfo.XSLTName ftrr2jats.xsl?><?ConverterInfo.Version 1?><?origin publisher?><front><journal-meta><journal-id journal-id-type="nlm-ta">Int J Infect Dis</journal-id><journal-id journal-id-type="iso-abbrev">Int. J. Infect. Dis</journal-id><journal-title-group><journal-title>International Journal of Infectious Diseases</journal-title></journal-title-group><issn pub-type="ppub">1201-9712</issn><issn pub-type="epub">1878-3511</issn><publisher><publisher-name>The Author(s). Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">7194601</article-id><article-id pub-id-type="publisher-id">S1201-9712(20)30277-0</article-id><article-id pub-id-type="doi">10.1016/j.ijid.2020.04.061</article-id><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>Mild versus severe COVID-19: Laboratory markers</article-title></title-group><contrib-group><contrib contrib-type="author" id="aut0005"><name><surname>Velavan</surname><given-names>Thirumalaisamy P.</given-names></name><email>velavan@medizin.uni-tuebingen.de</email><xref rid="aff0005" ref-type="aff">a</xref><xref rid="aff0010" ref-type="aff">b</xref><xref rid="aff0015" ref-type="aff">c</xref><xref rid="fn0005" ref-type="fn">1</xref><xref rid="cor0005" ref-type="corresp">&#x0204e;</xref></contrib><contrib contrib-type="author" id="aut0010"><name><surname>Meyer</surname><given-names>Christian G.</given-names></name><xref rid="aff0005" ref-type="aff">a</xref><xref rid="aff0010" ref-type="aff">b</xref><xref rid="aff0015" ref-type="aff">c</xref><xref rid="fn0005" ref-type="fn">1</xref></contrib><aff id="aff0005"><label>a</label>Institute of Tropical Medicine, Universit&#x000e4;tsklinikum T&#x000fc;bingen, Germany</aff><aff id="aff0010"><label>b</label>Vietnamese German Center for Medical Research, Hanoi, Vietnam</aff><aff id="aff0015"><label>c</label>Faculty of Medicine, Duy Tan University, Da Nang, Vietnam</aff></contrib-group><author-notes><corresp id="cor0005"><label>&#x0204e;</label>Corresponding author at: Institute of Tropical Medicine, Universit&#x000e4;tsklinikum T&#x000fc;bingen, Germany. Tel.: +49 7071 2985981. <email>velavan@medizin.uni-tuebingen.de</email></corresp><fn id="fn0005"><label>1</label><p id="npar0005">Both authors contributed equally.</p></fn></author-notes><pub-date pub-type="pmc-release"><day>25</day><month>4</month><year>2020</year></pub-date><!-- PMC Release delay is 0 months and 0 days and was based on <pub-date
						pub-type="epub">.--><pub-date pub-type="ppub"><month>6</month><year>2020</year></pub-date><pub-date pub-type="epub"><day>25</day><month>4</month><year>2020</year></pub-date><volume>95</volume><fpage>304</fpage><lpage>307</lpage><history><date date-type="received"><day>5</day><month>4</month><year>2020</year></date><date date-type="rev-recd"><day>15</day><month>4</month><year>2020</year></date><date date-type="accepted"><day>22</day><month>4</month><year>2020</year></date></history><permissions><copyright-statement>&#x000a9; 2020 The Author(s)</copyright-statement><copyright-year>2020</copyright-year><license><license-p>Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.</license-p></license></permissions><abstract abstract-type="author-highlights" id="abs0005"><title>Highlights</title><p><list list-type="simple" id="lis0005"><list-item id="lsti0005"><label>&#x02022;</label><p id="par0005">Several laboratory parameters may facilitate the assessment of COVID-19 severity</p></list-item><list-item id="lsti0010"><label>&#x02022;</label><p id="par0010">Discriminating mild from severe COVID-19 disease</p></list-item><list-item id="lsti0015"><label>&#x02022;</label><p id="par0015">Cumulative data from clinical characteristics of COVID-19 patients</p></list-item><list-item id="lsti0020"><label>&#x02022;</label><p id="par0020">Low lymphocyte count as well as the serum levels of CRP, D-dimers, ferritin and IL-6</p></list-item></list></p></abstract><abstract id="abs0010"><p>The number of COVID-19 patients is dramatically increasing worldwide. Treatment in intensive care units (ICU) has become a major challenge; therefore, early recognition of severe forms is absolutely essential for timely triaging of patients. While the clinical status, in particular peripheral oxygen saturation (SpO2) levels, and concurrent comorbidities of COVID-19 patients largely determine the need for their admittance to ICUs, several laboratory parameters may facilitate the assessment of disease severity. Clinicians should consider low lymphocyte count as well as the serum levels of CRP, D-dimers, ferritin, cardiac troponin and IL-6, which may be used in risk stratification to predict severe and fatal COVID-19 in hospitalised patients. It is more likely that the course of the disease will be unfavourable if some or all of these parameters are altered.</p></abstract><kwd-group id="kwd0005"><title>Keywords</title><kwd>Laboratory markers</kwd><kwd>COVID-19</kwd><kwd>Mild and severe COVID-19</kwd><kwd>Biomarkers</kwd></kwd-group></article-meta></front><body><p id="par0025">As the number of COVID-19 patients is dramatically increasing worldwide and treatment in intensive care units (ICU) has become a major challenge, early recognition of severe forms of COVID-19 is absolutely essential for timely triaging of patients. SARS-CoV-2 infection, especially in older patients and those with pre-existing illness, can progress to severe disease with critical respiratory symptoms and significant pulmonary changes visible by imaging techniques. The changes include ground glass opacities, patchy consolidation, alveolar exudates and interlobular involvement, ultimately prognosticating deterioration (<xref rid="bib0005" ref-type="bibr">Huang et al., 2020</xref>). Further to the recognised risk factors such as old age and underlying comorbidities&#x02013;particularly cardiovascular diseases, diabetes, respiratory diseases, and other conditions (<xref rid="bib0010" ref-type="bibr">Zhou et al., 2020</xref>)&#x02013;several markers have been identified that modulate the course of COVID-19. This paper summarises the laboratory markers that might be useful in indicating progression from mild to severe disease (<xref rid="tbl0005" ref-type="table">Table 1</xref>
).<table-wrap position="float" id="tbl0005"><label>Table 1</label><caption><p>Haematological, cytokine, liver enzyme and coagulation parameters in mild versus severe COVID19 patients.</p></caption><alt-text id="at0005">Table 1</alt-text><table frame="hsides" rules="groups"><thead><tr><th align="left"><bold>Haematological parameters</bold></th><th align="left"><bold>COVID-19 cases (n)</bold></th><th align="left"><bold>Interpretation</bold></th><th align="left"><bold>Reference</bold></th></tr></thead><tbody><tr><td align="left">White blood cell count (WBC)</td><td align="left">15 mild, 9 severe, 5 critical cases</td><td align="left">normal or &#x02193; in 23/29</td><td align="left">(<xref rid="bib0055" ref-type="bibr">Chen et al., 2020a</xref>)</td></tr><tr><td align="left"/><td align="left">41 cases (13 ICU cases)</td><td align="left">&#x02191; in ICU cases</td><td align="left">(<xref rid="bib0005" ref-type="bibr">Huang et al., 2020</xref>)</td></tr><tr><td align="left"/><td align="left">43 (28 mild, 15 severe)</td><td align="left">normal in all cases</td><td align="left">(<xref rid="bib0065" ref-type="bibr">Gao et al., 2020</xref>)</td></tr><tr><td align="left"/><td align="left">1,994 cases (meta-analysis)</td><td align="left">&#x02193; in 29% of cases</td><td align="left">(<xref rid="bib0075" ref-type="bibr">Li et al., 2020a</xref>)</td></tr><tr><td align="left"/><td align="left">54 cases</td><td align="left">normal in cases</td><td align="left">(<xref rid="bib0080" ref-type="bibr">Li et al., 2020b</xref>)</td></tr><tr><td align="left">Neutrophil count</td><td align="left">41 cases (13 ICU cases)</td><td align="left">&#x02191; in ICU cases</td><td align="left">(<xref rid="bib0005" ref-type="bibr">Huang et al., 2020</xref>)</td></tr><tr><td align="left"/><td align="left">201 cases</td><td align="left">&#x02191; in ARDS cases</td><td align="left">(<xref rid="bib0085" ref-type="bibr">Wu et al., 2020</xref>)</td></tr><tr><td align="left"/><td align="left">12 cases</td><td align="left">&#x02193; in most cases</td><td align="left">(<xref rid="bib0090" ref-type="bibr">Liu et al., 2020a</xref>)</td></tr><tr><td align="left">Lymphocyte count</td><td align="left">Familial cluster, 6 cases</td><td align="left">&#x02193;in 2 of 3 cases&#x000a0;&#x0003e;&#x000a0;60 years</td><td align="left">(<xref rid="bib0095" ref-type="bibr">Chan et al., 2020</xref>)</td></tr><tr><td align="left"/><td align="left">15 mild, 9 severe, 5 critical cases</td><td align="left">&#x02193; in 20/29</td><td align="left">(<xref rid="bib0055" ref-type="bibr">Chen et al., 2020a</xref>)</td></tr><tr><td align="left"/><td align="left">41 cases (13 ICU cases)</td><td align="left">&#x02193; in ICU cases</td><td align="left">(<xref rid="bib0005" ref-type="bibr">Huang et al., 2020</xref>)</td></tr><tr><td align="left"/><td align="left">140 cases</td><td align="left">&#x02193; in most cases</td><td align="left">(<xref rid="bib0100" ref-type="bibr">Zhang et al., 2020b</xref>)</td></tr><tr><td align="left"/><td align="left">43 (28 mild, 15 severe)</td><td align="left">normal in cases</td><td align="left">(<xref rid="bib0065" ref-type="bibr">Gao et al., 2020</xref>)</td></tr><tr><td align="left"/><td align="left">1,994 cases (meta-analysis)</td><td align="left">&#x02193; in most cases</td><td align="left">(<xref rid="bib0075" ref-type="bibr">Li et al., 2020a</xref>)</td></tr><tr><td align="left"/><td align="left">54 cases</td><td align="left">&#x02193; in most cases</td><td align="left">(<xref rid="bib0080" ref-type="bibr">Li et al., 2020b</xref>)</td></tr><tr><td align="left"/><td align="left">12 cases</td><td align="left">&#x02193; in most cases</td><td align="left">(<xref rid="bib0090" ref-type="bibr">Liu et al., 2020a</xref>)</td></tr><tr><td align="left"/><td align="left">30 cases</td><td align="left">&#x02193; in 40% cases</td><td align="left">(<xref rid="bib0105" ref-type="bibr">Liu et al., 2020b</xref>)</td></tr><tr><td align="left"/><td align="left">70 mild, 85 severe cases</td><td align="left">&#x02193; in all cases</td><td align="left">(<xref rid="bib0070" ref-type="bibr">Mo et al., 2020</xref>)</td></tr><tr><td align="left">Eosinophil count</td><td align="left">140 cases</td><td align="left">&#x02193; in most cases</td><td align="left">(<xref rid="bib0100" ref-type="bibr">Zhang et al., 2020b</xref>)</td></tr><tr><td align="left">Thrombocyte count</td><td align="left">Familial cluster, 6 cases</td><td align="left">&#x02193; in 2 of 3 cases&#x000a0;&#x0003e;&#x000a0;60 years</td><td align="left">(<xref rid="bib0095" ref-type="bibr">Chan et al., 2020</xref>)</td></tr><tr><td align="left"/><td align="left">70 mild, 85 severe cases</td><td align="left">normal; slightly lower in severe cases</td><td align="left">(<xref rid="bib0070" ref-type="bibr">Mo et al., 2020</xref>)</td></tr><tr><td align="left">Granulocyte-colony stimulating factor (G-CSF)</td><td align="left">41 cases (13 ICU cases)</td><td align="left">&#x02191; in ICU cases</td><td align="left">(<xref rid="bib0005" ref-type="bibr">Huang et al., 2020</xref>)</td></tr><tr><td align="left">CD8 cell count</td><td align="left">12 cases</td><td align="left">&#x02193; in most cases</td><td align="left">(<xref rid="bib0090" ref-type="bibr">Liu et al., 2020a</xref>)</td></tr></tbody></table><table frame="hsides" rules="groups"><thead><tr><th align="left"><bold>Cytokines</bold></th><th align="left"><bold>COVID-19 cases (n)</bold></th><th align="left"><bold>Interpretation</bold></th><th align="left"><bold>Reference</bold></th></tr></thead><tbody><tr><td align="left">Tumour necrosis factor alpha (TNF-alpha)</td><td align="left">41 cases (13 ICU cases)</td><td align="left">&#x02191; in ICU cases</td><td align="left">(<xref rid="bib0005" ref-type="bibr">Huang et al., 2020</xref>)</td></tr><tr><td align="left">Interferon-&#x003b3; induced protein 10 (IP-10)</td><td align="left">41 cases (13 ICU cases)</td><td align="left">&#x02191; in ICU cases</td><td align="left">(<xref rid="bib0005" ref-type="bibr">Huang et al., 2020</xref>)</td></tr><tr><td align="left">Monocyte chemoattractant protein 1 (MCP-1)</td><td align="left">41 cases (13 ICU cases)</td><td align="left">&#x02191; in ICU cases</td><td align="left">(<xref rid="bib0005" ref-type="bibr">Huang et al., 2020</xref>)</td></tr><tr><td align="left">Chemokine (C-C Motif) Ligand 3 (CCL-3)</td><td align="left">41 cases (13 ICU cases)</td><td align="left">&#x02191; in ICU cases</td><td align="left">(<xref rid="bib0005" ref-type="bibr">Huang et al., 2020</xref>)</td></tr><tr><td align="left">Interleukin-1 (IL-1)</td><td align="left">15 mild, 9 severe, 5 critical cases</td><td align="left">normal in all cases</td><td align="left">(<xref rid="bib0055" ref-type="bibr">Chen et al., 2020a</xref>)</td></tr><tr><td align="left">Interleukin-2 (IL-2)</td><td align="left">41 cases (13 ICU cases)</td><td align="left">&#x02191; in ICU cases</td><td align="left">(<xref rid="bib0005" ref-type="bibr">Huang et al., 2020</xref>)</td></tr><tr><td align="left">Interleukin-2 receptor (IL-2R)</td><td align="left">15 mild, 9 severe, 5 critical cases</td><td align="left">&#x02191;,&#x000a0;&#x0003e;&#x000a0;critical&#x000a0;&#x0003e;&#x000a0;severe&#x000a0;&#x0003e;&#x000a0;mild</td><td align="left">(<xref rid="bib0055" ref-type="bibr">Chen et al., 2020a</xref>)</td></tr><tr><td align="left">Interleukin-6 (IL-6)</td><td align="left">15 mild, 9 severe, 5 critical cases</td><td align="left">&#x02191; according to severity &#x0003e; critical&#x000a0;&#x0003e;&#x000a0;severe&#x000a0;&#x0003e;&#x000a0;mild</td><td align="left">(<xref rid="bib0055" ref-type="bibr">Chen et al., 2020a</xref>)</td></tr><tr><td align="left"/><td align="left">69 cases, mortality 7.5%</td><td align="left">&#x02191; in the patient group with SpO<sub>2</sub>&#x000a0;&#x0003c;&#x000a0;90%</td><td align="left">(<xref rid="bib0060" ref-type="bibr">Wang et al., 2020b</xref>)</td></tr><tr><td align="left"/><td align="left">150 cases</td><td align="left">&#x02191; in non-survivors</td><td align="left">(<xref rid="bib0035" ref-type="bibr">Mehta et al., 2020</xref>)</td></tr><tr><td align="left"/><td align="left">43: 28 mild, 15 severe cases</td><td align="left">&#x02191; in severe cases</td><td align="left">(<xref rid="bib0065" ref-type="bibr">Gao et al., 2020</xref>)</td></tr><tr><td align="left"/><td align="left">70 mild, 85 severe cases</td><td align="left">&#x02191;; higher in severe cases</td><td align="left">(<xref rid="bib0070" ref-type="bibr">Mo et al., 2020</xref>)</td></tr><tr><td align="left">Interleukin-7 (IL-7)</td><td align="left">41 cases (13 ICU cases)</td><td align="left">&#x02191; in ICU cases</td><td align="left">(<xref rid="bib0005" ref-type="bibr">Huang et al., 2020</xref>)</td></tr><tr><td align="left">Interleukin-8 (IL-8)</td><td align="left">15 mild, 9 severe, 5 critical cases</td><td align="left">normal in all cases</td><td align="left">(<xref rid="bib0055" ref-type="bibr">Chen et al., 2020a</xref>)</td></tr><tr><td align="left">Interleukin-10 (IL-10)</td><td align="left">15 mild, 9 severe, 5 critical cases</td><td align="left">normal in all cases</td><td align="left">(<xref rid="bib0055" ref-type="bibr">Chen et al., 2020a</xref>)</td></tr><tr><td align="left"/><td align="left">69 cases, mortality 7.5%</td><td align="left">&#x02191; in the patient group with SpO<sub>2</sub>&#x000a0;&#x0003c;&#x000a0;90%</td><td align="left">(<xref rid="bib0060" ref-type="bibr">Wang et al., 2020b</xref>)</td></tr><tr><td align="left"/><td align="left">41 cases (13 ICU cases)</td><td align="left">&#x02191; in ICU cases</td><td align="left">(<xref rid="bib0005" ref-type="bibr">Huang et al., 2020</xref>)</td></tr></tbody></table><table frame="hsides" rules="groups"><thead><tr><th align="left"><bold>Liver enzymes/biomarkers</bold></th><th align="left"><bold>COVID-19 cases (n)</bold></th><th align="left"><bold>Interpretation</bold></th><th align="left"><bold>Reference</bold></th></tr></thead><tbody><tr><td align="left">Albumin</td><td align="left">15 mild, 9 severe, 5 critical cases</td><td align="left">&#x02193;in 15/29</td><td align="left">(<xref rid="bib0055" ref-type="bibr">Chen et al., 2020a</xref>)</td></tr><tr><td align="left"/><td align="left">41 cases (13 ICU cases)</td><td align="left">&#x02193; in ICU cases</td><td align="left">(<xref rid="bib0005" ref-type="bibr">Huang et al., 2020</xref>)</td></tr><tr><td align="left"/><td align="left">12 cases</td><td align="left">&#x02193; in most cases</td><td align="left">(<xref rid="bib0090" ref-type="bibr">Liu et al., 2020a</xref>)</td></tr><tr><td align="left"/><td align="left">70 mild, 85 severe cases</td><td align="left">&#x02193; in all cases</td><td align="left">(<xref rid="bib0070" ref-type="bibr">Mo et al., 2020</xref>)</td></tr><tr><td align="left">Alanine aminotransferase (ALT)</td><td align="left">15 mild, 9 severe, 5 critical cases</td><td align="left">-</td><td align="left">(<xref rid="bib0055" ref-type="bibr">Chen et al., 2020a</xref>)</td></tr><tr><td align="left"/><td align="left">41 cases (13 ICU cases)</td><td align="left">&#x02191; in ICU cases</td><td align="left">(<xref rid="bib0005" ref-type="bibr">Huang et al., 2020</xref>)</td></tr><tr><td align="left">Aspartate aminotransferase (AST)</td><td align="left">15 mild, 9 severe, 5 critical cases</td><td align="left">-</td><td align="left">(<xref rid="bib0055" ref-type="bibr">Chen et al., 2020a</xref>)</td></tr><tr><td align="left">Total bilirubin</td><td align="left">41 cases (13 ICU cases)</td><td align="left">&#x02191; in ICU cases</td><td align="left">(<xref rid="bib0005" ref-type="bibr">Huang et al., 2020</xref>)</td></tr><tr><td align="left"/><td align="left">15 mild, 9 severe, 5 critical cases</td><td align="left">- normal in all cases</td><td align="left">(<xref rid="bib0055" ref-type="bibr">Chen et al., 2020a</xref>)</td></tr><tr><td align="left">Glucose</td><td align="left">43: 28 mild, 15 severe cases</td><td align="left">&#x02191; in severe cases</td><td align="left">(<xref rid="bib0065" ref-type="bibr">Gao et al., 2020</xref>)</td></tr><tr><td align="left">Serum creatinine</td><td align="left">126 mild, 24 severe cases</td><td align="left">&#x02191; in severe cases</td><td align="left">(<xref rid="bib0055" ref-type="bibr">Chen et al., 2020a</xref>)</td></tr><tr><td align="left">Lactate dehydrogenase (LDH)</td><td align="left">Familial cluster, 6 cases</td><td align="left">&#x02191; in the 3 cases &#x0003e;60 yrs.</td><td align="left">(<xref rid="bib0095" ref-type="bibr">Chan et al., 2020</xref>)</td></tr><tr><td align="left"/><td align="left">15 mild, 9 severe, 5 critical cases</td><td align="left">&#x02191; in 20/29</td><td align="left">(<xref rid="bib0055" ref-type="bibr">Chen et al., 2020a</xref>)</td></tr><tr><td align="left"/><td align="left">69 cases, mortality 7,5%</td><td align="left">&#x02191; in the patient group with SpO<sub>2</sub>&#x000a0;&#x0003c;&#x000a0;90%</td><td align="left">(<xref rid="bib0060" ref-type="bibr">Wang et al., 2020b</xref>)</td></tr><tr><td align="left"/><td align="left">41 cases (13 ICU cases)</td><td align="left">&#x02191; in ICU cases</td><td align="left">(<xref rid="bib0005" ref-type="bibr">Huang et al., 2020</xref>)</td></tr><tr><td align="left"/><td align="left">201 cases</td><td align="left">&#x02191; in ARDS cases</td><td align="left">(<xref rid="bib0085" ref-type="bibr">Wu et al., 2020</xref>)</td></tr><tr><td align="left"/><td align="left">1,994 cases (meta-analysis)</td><td align="left">&#x02191; in 28% of cases</td><td align="left">(<xref rid="bib0075" ref-type="bibr">Li et al., 2020a</xref>)</td></tr><tr><td align="left"/><td align="left">54 cases</td><td align="left">&#x02191; in most cases</td><td align="left">(<xref rid="bib0080" ref-type="bibr">Li et al., 2020b</xref>)</td></tr><tr><td align="left"/><td align="left">12 cases</td><td align="left">&#x02191; in all cases</td><td align="left">(<xref rid="bib0090" ref-type="bibr">Liu et al., 2020a</xref>)</td></tr><tr><td align="left"/><td align="left">70 mild, 85 severe cases</td><td align="left">&#x02191; in severe cases</td><td align="left">(<xref rid="bib0070" ref-type="bibr">Mo et al., 2020</xref>)</td></tr><tr><td align="left">C-reactive protein (CRP)</td><td align="left">Familial cluster, 6 cases</td><td align="left">&#x02191; in the 3 cases &#x0003e;60 yrs.</td><td align="left">(<xref rid="bib0095" ref-type="bibr">Chan et al., 2020</xref>)</td></tr><tr><td align="left"/><td align="left">126 mild, 24 severe cases</td><td align="left">higher in severe cases</td><td align="left">(<xref rid="bib0110" ref-type="bibr">Chen et al., 2020b</xref>)</td></tr><tr><td align="left"/><td align="left">15 mild, 9 severe, 5 critical cases</td><td align="left">&#x02191; in 27/29</td><td align="left">(<xref rid="bib0055" ref-type="bibr">Chen et al., 2020a</xref>)</td></tr><tr><td align="left"/><td align="left">69 cases, mortality 7,5%</td><td align="left">&#x02191; in cases with SpO<sub>2</sub>&#x000a0;&#x0003c;&#x000a0;90%</td><td align="left">(<xref rid="bib0060" ref-type="bibr">Wang et al., 2020b</xref>)</td></tr><tr><td align="left"/><td align="left">140 cases</td><td align="left">&#x02191; in severe cases</td><td align="left">(<xref rid="bib0100" ref-type="bibr">Zhang et al., 2020b</xref>)</td></tr><tr><td align="left"/><td align="left">43: 28 mild, 15 severe cases</td><td align="left">&#x02191; in severe cases</td><td align="left">(<xref rid="bib0065" ref-type="bibr">Gao et al., 2020</xref>)</td></tr><tr><td align="left"/><td align="left">1,994 cases (meta-analysis)</td><td align="left">&#x02191; in 44% of cases</td><td align="left">(<xref rid="bib0075" ref-type="bibr">Li et al., 2020a</xref>)</td></tr><tr><td align="left"/><td align="left">54 cases</td><td align="left">&#x02191; in most cases</td><td align="left">(<xref rid="bib0080" ref-type="bibr">Li et al., 2020b</xref>)</td></tr><tr><td align="left"/><td align="left">12 cases</td><td align="left">&#x02191; in most cases</td><td align="left">(<xref rid="bib0090" ref-type="bibr">Liu et al., 2020a</xref>)</td></tr><tr><td align="left"/><td align="left">70 mild, 85 severe cases</td><td align="left">&#x02191; in all cases, higher in severe cases</td><td align="left">(<xref rid="bib0070" ref-type="bibr">Mo et al., 2020</xref>)</td></tr><tr><td align="left">Procalcitonin (PCT)</td><td align="left">140 cases</td><td align="left">&#x02191; in severe cases</td><td align="left">(<xref rid="bib0100" ref-type="bibr">Zhang et al., 2020b</xref>)</td></tr><tr><td align="left"/><td align="left">70 mild, 85 severe cases</td><td align="left">&#x02191; in all cases</td><td align="left">(<xref rid="bib0070" ref-type="bibr">Mo et al., 2020</xref>)</td></tr><tr><td align="left">Ferritin</td><td align="left">150</td><td align="left">&#x02191; in non-survivors</td><td align="left">(<xref rid="bib0035" ref-type="bibr">Mehta et al., 2020</xref>)</td></tr><tr><td align="left">NT-proBNP</td><td align="left">126 mild, 24 severe cases</td><td align="left">&#x02191; in severe cases</td><td align="left">(<xref rid="bib0110" ref-type="bibr">Chen et al., 2020b</xref>)</td></tr><tr><td align="left">Cardiac troponin I</td><td align="left">126 mild, 24 severe cases</td><td align="left">&#x02191; in severe cases</td><td align="left">(<xref rid="bib0110" ref-type="bibr">Chen et al., 2020b</xref>)</td></tr><tr><td align="left">Cardiac troponin I (meta-analysis)</td><td align="left">218 mild, 123 severe cases</td><td align="left">&#x02191; in severe cases</td><td align="left">(<xref rid="bib0045" ref-type="bibr">Lippi et al., 2020</xref>)</td></tr><tr><td align="left"/><td align="left">138 hospitalised severe cases</td><td align="left">&#x02191; in severe cases</td><td align="left">(<xref rid="bib0050" ref-type="bibr">Wang et al., 2020a</xref>)</td></tr><tr><td align="left">Angiotensin II level</td><td align="left">12 cases</td><td align="left">&#x02191; in cases</td><td align="left">(<xref rid="bib0090" ref-type="bibr">Liu et al., 2020a</xref>)</td></tr></tbody></table><table frame="hsides" rules="groups"><thead><tr><th align="left"><bold>Coagulation parameters</bold></th><th align="left"><bold>COVID-19 cases(n)</bold></th><th align="left"><bold>Interpretation</bold></th><th align="left"><bold>Reference</bold></th></tr></thead><tbody><tr><td align="left">d-dimers</td><td align="left">191 cases, 91 with comorbidities</td><td align="left">&#x02191; in non-survivors</td><td align="left">(<xref rid="bib0010" ref-type="bibr">Zhou et al., 2020</xref>)</td></tr><tr><td align="left"/><td align="left">94 cases</td><td align="left">&#x02191; in cases vs. controls</td><td align="left">(<xref rid="bib0115" ref-type="bibr">Han et al., 2020</xref>)</td></tr><tr><td align="left"/><td align="left">201 cases</td><td align="left">&#x02191; in ARDS cases</td><td align="left">(<xref rid="bib0085" ref-type="bibr">Wu et al., 2020</xref>)</td></tr><tr><td align="left"/><td align="left">140 cases</td><td align="left">&#x02191; in severe cases</td><td align="left">(<xref rid="bib0100" ref-type="bibr">Zhang et al., 2020b</xref>)</td></tr><tr><td align="left"/><td align="left">43: 28 mild, 15 severe cases</td><td align="left">&#x02191; in severe cases</td><td align="left">(<xref rid="bib0065" ref-type="bibr">Gao et al., 2020</xref>)</td></tr><tr><td align="left"/><td align="left">30 cases</td><td align="left">&#x02191; in 17% of cases</td><td align="left">(<xref rid="bib0105" ref-type="bibr">Liu et al., 2020b</xref>)</td></tr><tr><td align="left"/><td align="left">70 mild, 85 severe cases</td><td align="left">normal; slightly higher in severe cases</td><td align="left">(<xref rid="bib0070" ref-type="bibr">Mo et al., 2020</xref>)</td></tr><tr><td align="left"/><td align="left">183 cases; 21 non-survivors</td><td align="left">&#x02191; in all cases, higher in non-survivors</td><td align="left">(<xref rid="bib0040" ref-type="bibr">Tang et al., 2020</xref>)</td></tr><tr><td align="left">Antithrombin (AT)</td><td align="left">94 cases</td><td align="left">&#x02193; in cases vs. controls</td><td align="left">(<xref rid="bib0115" ref-type="bibr">Han et al., 2020</xref>)</td></tr><tr><td align="left">Prothrombin time (PT)</td><td align="left">94 cases</td><td align="left">&#x02193; in cases vs. controls</td><td align="left">(<xref rid="bib0115" ref-type="bibr">Han et al., 2020</xref>)</td></tr><tr><td align="left"/><td align="left">41 cases (13 ICU cases)</td><td align="left">&#x02191; in ICU cases</td><td align="left">(<xref rid="bib0005" ref-type="bibr">Huang et al., 2020</xref>)</td></tr><tr><td align="left"/><td align="left">183 cases; 21 non-survivors</td><td align="left">&#x02191; in non-survivors</td><td align="left">(<xref rid="bib0040" ref-type="bibr">Tang et al., 2020</xref>)</td></tr><tr><td align="left">Activated partial thromboplastin time (APTT)</td><td align="left">183 cases; 21 non-survivors</td><td align="left">&#x02191; in non-survivors</td><td align="left">(<xref rid="bib0040" ref-type="bibr">Tang et al., 2020</xref>)</td></tr><tr><td align="left">Thrombin clotting time (TCT)</td><td align="left">94 cases</td><td align="left">shorter in critical cases vs. controls</td><td align="left">(<xref rid="bib0115" ref-type="bibr">Han et al., 2020</xref>)</td></tr><tr><td align="left"/><td align="left">43: 28 mild, 15 severe cases</td><td align="left">&#x02191; in severe cases</td><td align="left">(<xref rid="bib0065" ref-type="bibr">Gao et al., 2020</xref>)</td></tr><tr><td align="left">Fibrin degradation products (FDP)</td><td align="left">94 cases</td><td align="left">&#x02191; in cases vs. controls</td><td align="left">(<xref rid="bib0115" ref-type="bibr">Han et al., 2020</xref>)</td></tr><tr><td align="left"/><td align="left">183 cases; 21 non-survivors</td><td align="left">&#x02191; in non-survivors</td><td align="left">(<xref rid="bib0040" ref-type="bibr">Tang et al., 2020</xref>)</td></tr><tr><td align="left">Fibrinogen</td><td align="left">94 cases</td><td align="left">&#x02191; in cases vs. controls</td><td align="left">(<xref rid="bib0115" ref-type="bibr">Han et al., 2020</xref>)</td></tr><tr><td align="left"/><td align="left">43: 28 mild, 15 severe cases</td><td align="left">&#x02191; in severe cases</td><td align="left">(<xref rid="bib0065" ref-type="bibr">Gao et al., 2020</xref>)</td></tr><tr><td align="left"/><td align="left">183 cases; 21 non-survivors</td><td align="left">&#x02191; in all cases, higher in non-survivors</td><td align="left">(<xref rid="bib0040" ref-type="bibr">Tang et al., 2020</xref>)</td></tr></tbody></table><table-wrap-foot><fn><p><bold>Abbreviations:</bold> ARDS, acute respiratory distress syndrome; ICU, intensive care unit; CD8, cluster of differentiation 8; SpO<sub>2</sub>, Peripheral oxygen saturation; NT-proBNP, N-terminal pro b-type natriuretic peptide</p></fn></table-wrap-foot></table-wrap></p><p id="par0030">COVID-19 patients admitted to ICUs have been found to have higher concentrations of proinflammatory cytokines and, importantly, increased secretion of those T-helper-2 (Th2) cytokines suppressing inflammation (<xref rid="bib0005" ref-type="bibr">Huang et al., 2020</xref>). Given the high levels of cytokines induced by SARS-CoV-2, treatment to reduce inflammation-related lung damage is critical. However, any intervention to reduce inflammation will negatively affect viral clearance. Among the various inflammatory cytokine and chemokine levels assessed in several studies, tumour necrosis factor alpha (TNF-&#x003b1;), interferon-&#x003b3;-induced protein 10 (IP-10), monocyte chemoattractant protein 1 (MCP-1), chemokine (C-C motif), ligand 3 (CCL-3), and distinct interleukins (IL) (IL-2, IL-6, IL-7, IL-10) were significantly associated with disease severity and particularly observed among cases admitted to ICUs. IL-1 and IL-8 were not associated with severity (<xref rid="tbl0005" ref-type="table">Table 1</xref>). Apparently, the serum levels of some interleukins have the potential to discriminate between mild and severe disease and possibly may be used as prognostic markers.</p><p id="par0035">Among haematological parameters, lymphopenia is clearly associated with disease severity; patients who have died from COVID-19 have had significantly lower lymphocyte counts than survivors. In fact, repletion of lymphocytes may be an important factor for recovery (<xref rid="bib0015" ref-type="bibr">Henry, 2020</xref>). Other blood cells&#x02013;including white blood cells, neutrophils, eosinophils, platelets, and CD8 cell counts&#x02013;were partial predictors in discriminating mild from severe COVID-19 (<xref rid="tbl0005" ref-type="table">Table 1</xref>); their significance is still ambiguous. Granulocyte colony stimulating factor (G-CSF) has been found to be elevated in ICU patients and significantly associated with disease severity (<xref rid="tbl0005" ref-type="table">Table 1</xref>).</p><p id="par0040">Patients with severe COVID-19 appear to have more frequent signs of liver dysfunction than those with milder disease. An increase in alanine aminotransferase (ALT), aspartate aminotransferase (AST) and total bilirubin levels has been observed among many ICU patients (<xref rid="bib0020" ref-type="bibr">Zhang et al., 2020a</xref>) (<xref rid="tbl0005" ref-type="table">Table 1</xref>). Infection of liver cells with SARS-CoV-2 cannot be excluded as 2&#x02013;10% of patients with COVID-19 have diarrhoea and viral RNA has been detected in both stool and blood samples, which implies the possibility of hepatic virus presence (<xref rid="bib0025" ref-type="bibr">Yeo et al., 2020</xref>). It is also likely that any immune-mediated inflammation, in particular cytokine storm, but also pneumonia-associated hypoxia, may lead to liver damage in critically ill COVID-19 patients (<xref rid="bib0020" ref-type="bibr">Zhang et al., 2020a</xref>). C-reactive protein (CRP) levels are increased in COVID-19 patients and it has been shown that survivors had median CRP values of approximately 40&#x000a0;mg/L, while non-survivors had median values of 125&#x000a0;mg/L, indicating a strong correlation with disease severity and prognosis (<xref rid="bib0030" ref-type="bibr">Ruan et al., 2020</xref>) (<xref rid="tbl0005" ref-type="table">Table 1</xref>). Other predictors of poor outcome include the serum levels of ferritin and lactate dehydrogenase (LDH). Elevated ferritin levels due to secondary haemophagocytic lymphohistiocytosis (sHLH) and cytokine storm syndrome have been reported in severe COVID-19 patients. Based on body temperature, organomegaly, blood cell cytopenia, triglycerides, fibrinogen, AST and ferritin levels, a predictive H-score has been proposed to estimate the risk of developing secondary haemophagocytic lymphohistiocytosis (<xref rid="bib0035" ref-type="bibr">Mehta et al., 2020</xref>).</p><p id="par0045">Correlations of abnormal coagulation parameters with poor prognosis have been observed (<xref rid="tbl0005" ref-type="table">Table 1</xref>). Non-survivors have shown significantly higher levels of plasma D-dimers and fibrin degradation products, increased prothrombin times and activated partial thromboplastin times compared to survivors (<xref rid="bib0040" ref-type="bibr">Tang et al., 2020</xref>). Coagulopathy and overt disseminated intravascular coagulation appear to be associated with high mortality rates. Among the coagulation parameters, D-dimer elevation &#x0003e; 1 ug/L was the strongest independent predictor of mortality (<xref rid="bib0010" ref-type="bibr">Zhou et al., 2020</xref>). Elevated cardiac troponin I levels indicating heart injury were also predictive of mortality in critically ill patients (<xref rid="bib0045" ref-type="bibr">Lippi et al., 2020</xref>, <xref rid="bib0050" ref-type="bibr">Wang et al., 2020a</xref>).</p><p id="par0050">The haematological and coagulation parameters summarised here and increased inflammatory reactions caused by various cytokines and liver enzymes are a globally observed phenomenon in COVID-19 patients. While the clinical status (in particular SpO<sub>2</sub> levels) and concurrent comorbidities of COVID-19 patients largely determine the need for their admittance to ICUs, several laboratory parameters may facilitate the assessment of disease severity and rational triaging. It is more likely that the course of the disease will be unfavourable if some or all of these parameters are altered. Clinicians should consider low lymphocyte count and the serum levels of CRP, D-dimers, ferritin, cardiac troponin and IL-6, which may be used in risk stratification to predict severe and fatal COVID-19 in hospitalised patients. In order to further support clinical decision-making, large datasets and sound meta-analyses are now urgently required.</p><sec id="sec0005"><title>Conflict of interest</title><p id="par0055">All authors disclose no conflict of interest.</p></sec><sec id="sec0010"><title>Funding Source</title><p id="par0060">European and Developing Countries Clinical Trials Partnership (EDCTP) Pan African Network for Rapid Research, Response, and Preparedness for Infectious Diseases Epidemics consortium (PANDORA-ID-NET- EDCTP grant ID: RIA2016E-1609).</p></sec></body><back><ref-list id="bibl0005"><title>References</title><ref id="bib0005"><element-citation publication-type="journal" id="sbref0005"><person-group person-group-type="author"><name><surname>Huang</surname><given-names>C.</given-names></name><name><surname>Wang</surname><given-names>Y.</given-names></name><name><surname>Li</surname><given-names>X.</given-names></name></person-group><article-title>Clinical features of patients infected with 2019 novel coronavirus in Wuhan</article-title><source>China. Lancet.</source><volume>395</volume><year>2020</year><fpage>497</fpage><lpage>506</lpage><pub-id pub-id-type="pmid">31986264</pub-id></element-citation></ref><ref id="bib0010"><element-citation publication-type="journal" id="sbref0010"><person-group person-group-type="author"><name><surname>Zhou</surname><given-names>F.</given-names></name><name><surname>Yu</surname><given-names>T.</given-names></name><name><surname>Du</surname><given-names>R.</given-names></name></person-group><article-title>Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan</article-title><source>China: a retrospective cohort study. Lancet</source><year>2020</year></element-citation></ref><ref id="bib0015"><element-citation publication-type="book" id="sbref0015"><person-group person-group-type="author"><name><surname>Henry</surname><given-names>B.M.</given-names></name></person-group><chapter-title>COVID-19, ECMO, and lymphopenia: a word of caution</chapter-title><year>2020</year><publisher-name>Lancet Respir Med</publisher-name></element-citation></ref><ref id="bib0020"><element-citation publication-type="book" id="sbref0020"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>C.</given-names></name><name><surname>Shi</surname><given-names>L.</given-names></name><name><surname>Wang</surname><given-names>F.S.</given-names></name></person-group><chapter-title>Liver injury in COVID-19: management and challenges</chapter-title><year>2020</year><publisher-name>Lancet Gastroenterol Hepatol</publisher-name></element-citation></ref><ref id="bib0025"><element-citation publication-type="journal" id="sbref0025"><person-group person-group-type="author"><name><surname>Yeo</surname><given-names>C.</given-names></name><name><surname>Kaushal</surname><given-names>S.</given-names></name><name><surname>Yeo</surname><given-names>D.</given-names></name></person-group><article-title>Enteric involvement of coronaviruses: is faecal-oral transmission of SARS-CoV-2 possible?</article-title><source>Lancet Gastroenterol Hepatol.</source><volume>5</volume><year>2020</year><fpage>335</fpage><lpage>337</lpage><pub-id pub-id-type="pmid">32087098</pub-id></element-citation></ref><ref id="bib0030"><element-citation publication-type="journal" id="sbref0030"><person-group person-group-type="author"><name><surname>Ruan</surname><given-names>Q.</given-names></name><name><surname>Yang</surname><given-names>K.</given-names></name><name><surname>Wang</surname><given-names>W.</given-names></name><name><surname>Jiang</surname><given-names>L.</given-names></name><name><surname>Song</surname><given-names>J.</given-names></name></person-group><article-title>Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan</article-title><source>China. Intensive Care Med</source><year>2020</year></element-citation></ref><ref id="bib0035"><element-citation publication-type="book" id="sbref0035"><person-group person-group-type="author"><name><surname>Mehta</surname><given-names>P.</given-names></name><name><surname>McAuley</surname><given-names>D.F.</given-names></name><name><surname>Brown</surname><given-names>M.</given-names></name><name><surname>Sanchez</surname><given-names>E.</given-names></name><name><surname>Tattersall</surname><given-names>R.S.</given-names></name><name><surname>Manson</surname><given-names>J.J.</given-names></name></person-group><chapter-title>COVID-19: consider cytokine storm syndromes and immunosuppression</chapter-title><year>2020</year><publisher-name>Lancet</publisher-name></element-citation></ref><ref id="bib0040"><element-citation publication-type="journal" id="sbref0040"><person-group person-group-type="author"><name><surname>Tang</surname><given-names>N.</given-names></name><name><surname>Li</surname><given-names>D.</given-names></name><name><surname>Wang</surname><given-names>X.</given-names></name><name><surname>Sun</surname><given-names>Z.</given-names></name></person-group><article-title>Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia</article-title><source>J Thromb Haemost.</source><year>2020</year></element-citation></ref><ref id="bib0045"><element-citation publication-type="journal" id="sbref0045"><person-group person-group-type="author"><name><surname>Lippi</surname><given-names>G.</given-names></name><name><surname>Lavie</surname><given-names>C.J.</given-names></name><name><surname>Sanchis-Gomar</surname><given-names>F.</given-names></name></person-group><article-title>Cardiac troponin I in patients with coronavirus disease 2019 (COVID-19): Evidence from a meta-analysis</article-title><source>Prog Cardiovasc Dis.</source><year>2020</year></element-citation></ref><ref id="bib0050"><element-citation publication-type="book" id="sbref0050"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>D.</given-names></name><name><surname>Hu</surname><given-names>B.</given-names></name><name><surname>Hu</surname><given-names>C.</given-names></name></person-group><chapter-title>Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan</chapter-title><year>2020</year><publisher-name>JAMA</publisher-name><publisher-loc>China</publisher-loc></element-citation></ref><ref id="bib0055"><element-citation publication-type="journal" id="sbref0055"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>L.</given-names></name><name><surname>Liu</surname><given-names>H.G.</given-names></name><name><surname>Liu</surname><given-names>W.</given-names></name></person-group><article-title>Analysis of clinical features of 29 patients with 2019 novel coronavirus pneumonia</article-title><source>Zhonghua Jie He He Hu Xi Za Zhi.</source><volume>43</volume><year>2020</year><fpage>203</fpage><lpage>208</lpage><pub-id pub-id-type="pmid">32164089</pub-id></element-citation></ref><ref id="bib0060"><element-citation publication-type="book" id="sbref0060"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>Z.</given-names></name><name><surname>Yang</surname><given-names>B.</given-names></name><name><surname>Li</surname><given-names>Q.</given-names></name><name><surname>Wen</surname><given-names>L.</given-names></name><name><surname>Zhang</surname><given-names>R.</given-names></name></person-group><chapter-title>Clinical Features of 69 Cases with Coronavirus Disease 2019 in Wuhan</chapter-title><year>2020</year><publisher-name>Clin Infect Dis</publisher-name><publisher-loc>China</publisher-loc></element-citation></ref><ref id="bib0065"><element-citation publication-type="journal" id="sbref0065"><person-group person-group-type="author"><name><surname>Gao</surname><given-names>Y.</given-names></name><name><surname>Li</surname><given-names>T.</given-names></name><name><surname>Han</surname><given-names>M.</given-names></name></person-group><article-title>Diagnostic Utility of Clinical Laboratory Data Determinations for Patients with the Severe COVID-19</article-title><source>J Med Virol.</source><year>2020</year></element-citation></ref><ref id="bib0070"><element-citation publication-type="journal" id="sbref0070"><person-group person-group-type="author"><name><surname>Mo</surname><given-names>P.</given-names></name><name><surname>Xing</surname><given-names>Y.</given-names></name><name><surname>Xiao</surname><given-names>Y.</given-names></name></person-group><article-title>Clinical characteristics of refractory COVID-19 pneumonia in Wuhan</article-title><source>China. Clin Infect Dis.</source><year>2020</year></element-citation></ref><ref id="bib0075"><element-citation publication-type="journal" id="sbref0075"><person-group person-group-type="author"><name><surname>Li</surname><given-names>L.Q.</given-names></name><name><surname>Huang</surname><given-names>T.</given-names></name><name><surname>Wang</surname><given-names>Y.Q.</given-names></name></person-group><article-title>2019 novel coronavirus patients&#x02019; clinical characteristics, discharge rate and fatality rate of meta-analysis</article-title><source>J Med Virol.</source><year>2020</year></element-citation></ref><ref id="bib0080"><element-citation publication-type="journal" id="sbref0080"><person-group person-group-type="author"><name><surname>Li</surname><given-names>Y.Y.</given-names></name><name><surname>Wang</surname><given-names>W.N.</given-names></name><name><surname>Lei</surname><given-names>Y.</given-names></name></person-group><article-title>Comparison of the clinical characteristics between RNA positive and negative patients clinically diagnosed with 2019 novel coronavirus pneumonia</article-title><source>Zhonghua Jie He He Hu Xi Za Zhi.</source><volume>43</volume><year>2020</year><fpage>E023</fpage></element-citation></ref><ref id="bib0085"><element-citation publication-type="book" id="sbref0085"><person-group person-group-type="author"><name><surname>Wu</surname><given-names>C.</given-names></name><name><surname>Chen</surname><given-names>X.</given-names></name><name><surname>Cai</surname><given-names>Y.</given-names></name></person-group><chapter-title>Risk Factors Associated With Acute Respiratory Distress Syndrome and Death in Patients With Coronavirus Disease 2019 Pneumonia in Wuhan</chapter-title><year>2020</year><publisher-name>JAMA Intern Med</publisher-name><publisher-loc>China</publisher-loc></element-citation></ref><ref id="bib0090"><element-citation publication-type="journal" id="sbref0090"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>Y.</given-names></name><name><surname>Yang</surname><given-names>Y.</given-names></name><name><surname>Zhang</surname><given-names>C.</given-names></name></person-group><article-title>Clinical and biochemical indexes from 2019-nCoV infected patients linked to viral loads and lung injury</article-title><source>Sci China Life Sci.</source><volume>63</volume><year>2020</year><fpage>364</fpage><lpage>374</lpage><pub-id pub-id-type="pmid">32048163</pub-id></element-citation></ref><ref id="bib0095"><element-citation publication-type="journal" id="sbref0095"><person-group person-group-type="author"><name><surname>Chan</surname><given-names>J.F.</given-names></name><name><surname>Yuan</surname><given-names>S.</given-names></name><name><surname>Kok</surname><given-names>K.H.</given-names></name></person-group><article-title>A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster</article-title><source>Lancet.</source><volume>395</volume><year>2020</year><fpage>514</fpage><lpage>523</lpage><pub-id pub-id-type="pmid">31986261</pub-id></element-citation></ref><ref id="bib0100"><element-citation publication-type="book" id="sbref0100"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>J.J.</given-names></name><name><surname>Dong</surname><given-names>X.</given-names></name><name><surname>Cao</surname><given-names>Y.Y.</given-names></name></person-group><chapter-title>Clinical characteristics of 140 patients infected with SARS-CoV-2 in Wuhan</chapter-title><year>2020</year><publisher-name>Allergy</publisher-name><publisher-loc>China</publisher-loc></element-citation></ref><ref id="bib0105"><element-citation publication-type="journal" id="sbref0105"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>M.</given-names></name><name><surname>He</surname><given-names>P.</given-names></name><name><surname>Liu</surname><given-names>H.G.</given-names></name></person-group><article-title>Clinical characteristics of 30 medical workers infected with new coronavirus pneumonia</article-title><source>Zhonghua Jie He He Hu Xi Za Zhi.</source><volume>43</volume><year>2020</year><fpage>E016</fpage><pub-id pub-id-type="pmid">32062957</pub-id></element-citation></ref><ref id="bib0110"><element-citation publication-type="journal" id="sbref0110"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>C.</given-names></name><name><surname>Chen</surname><given-names>C.</given-names></name><name><surname>Yan</surname><given-names>J.T.</given-names></name><name><surname>Zhou</surname><given-names>N.</given-names></name><name><surname>Zhao</surname><given-names>J.P.</given-names></name><name><surname>Wang</surname><given-names>D.W.</given-names></name></person-group><article-title>Analysis of myocardial injury in patients with COVID-19 and association between concomitant cardiovascular diseases and severity of COVID-19</article-title><source>Zhonghua Xin Xue Guan Bing Za Zhi.</source><volume>48</volume><year>2020</year><fpage>E008</fpage><pub-id pub-id-type="pmid">32141280</pub-id></element-citation></ref><ref id="bib0115"><element-citation publication-type="journal" id="sbref0115"><person-group person-group-type="author"><name><surname>Han</surname><given-names>H.</given-names></name><name><surname>Yang</surname><given-names>L.</given-names></name><name><surname>Liu</surname><given-names>R.</given-names></name></person-group><article-title>Prominent changes in blood coagulation of patients with SARS-CoV-2 infection</article-title><source>Clin Chem Lab Med.</source><year>2020</year></element-citation></ref></ref-list><ack id="ack0005"><title>Acknowledgements</title><p>All authors have an academic interest and contributed equally. TPV is a member of the Pan African Network for Rapid Research, Response, and Preparedness for Infectious Diseases Epidemics consortium (PANDORA-ID-NET).</p></ack></back></article>